Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review (Q36162401)

From Wikidata

Jump to navigation Jump to search

scientific article

Sprache	Label	Description	Also known as
Englisch	Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

2 references

25 October 2022

10 January 2024

1 reference

PubMed publication ID

systematic review

1 reference

PubMed publication ID

Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review (English)

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

human immunodeficiency virus infectious disease

1 reference

1 July 2020

reverse-transcriptase inhibitor

1 reference

2 October 2019

1 reference

3 November 2019

1 reference

based on heuristic

inferred from abstract

anti-HIV agents

1 reference

18 December 2020

highly active antiretroviral therapy

1 reference

26 January 2021

1 reference

based on heuristic

inferred from abstract

1 reference

PubMed publication ID

heterotricyclic compound

1 reference

PubMed publication ID

object named as

Hacsi Horvath

2

0 references

George Rutherford

1

object named as

George W Rutherford

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

language of work or name

0 references

publication date

13 October 2016

14 references

Europe PubMed Central

PMC publication ID

12 August 2017

23 March 2019

22 June 2019

25 June 2019

2 October 2019

19 October 2019

3 November 2019

26 April 2020

1 July 2020

18 December 2020

22 January 2021

26 January 2021

25 October 2022

10 January 2024

14 references

Europe PubMed Central

PMC publication ID

12 August 2017

23 March 2019

22 June 2019

25 June 2019

2 October 2019

19 October 2019

3 November 2019

26 April 2020

1 July 2020

18 December 2020

22 January 2021

26 January 2021

25 October 2022

10 January 2024

11

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

10

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

e0162775

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

copyright license

Creative Commons Attribution 4.0 International

2 references

Europe PubMed Central

25 October 2022

Europe PubMed Central

10 January 2024

copyright status

0 references

on focus list of Wikimedia project

0 references

Clinical effectiveness of dolutegravir in the treatment of HIV/AIDS

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5063380

2 October 2017

Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5063380

2 October 2017

Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5063380

2 October 2017

Will drug resistance against dolutegravir in initial therapy ever occur?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5063380

2 October 2017

Comparative Safety and Neuropsychiatric Adverse Events Associated With Efavirenz Use in First-Line Antiretroviral Therapy: A Systematic Review and Meta-Analysis of Randomized Trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5063380

2 October 2017

Genetic barrier to resistance for dolutegravir.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5063380

2 October 2017

Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5063380

2 October 2017

Dolutegravir: clinical and laboratory safety in integrase inhibitor-naive patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5063380

2 October 2017

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5063380

2 October 2017

Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5063380

2 October 2017

Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5063380

2 October 2017

World Health Organization guideline development: an evaluation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5063380

2 October 2017

Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5063380

2 October 2017

GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5063380

2 October 2017

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5063380

2 October 2017

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5063380

2 July 2018

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5063380

23 September 2018

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0162775

21 January 2018

British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5063380

5 December 2018

Identifiers

10.1371/JOURNAL.PONE.0162775

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

2016PLoSO..1162775R

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36162401&oldid=2050477944"